Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
J. J. Kavanagh, D. M. Gershenson, H. Choi, L. Lewis, K. Patel, G. L. Brown, A. Garcia, D. R. Spriggs
International Journal of Gynecologic Cancer Jun 2005, 15 (4) 593-600; DOI: 10.1136/ijgc-00009577-200507000-00003